ExpreS2ion will participate at key industry and investor events in March 2022
Hørsholm, Denmark, March 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March. These include Aktiespararna’s Aktiedagen (March 14), the Swiss Nordic Bio event (March 23), and BIO-Europe Spring (March 28-31).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below.
Aktiespararna’s Aktiedagen, March 14, at 20.00-20.30
See the company presentation by our CEO Bent U. Frandsen at this investor event. It is possible to follow the event online, or attend the meeting by reserving a seat at Aktiespararna's website.
Swiss Nordic Bio, Zürich, Switzerland, March 23
To pre-arrange investor/business meetings with our CEO Bent U. Frandsen, please contact us via email on info@expreS2ionbio.com. More information is available at the event website Swiss Nordic Bio.
BIO-Europe Spring, March 28-31, Digital
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information is available at BIO-Europe’s website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.